Ex Officio Participants in the Working Group on Ci- vilian Biodefense: George Counts, MD, CDC; Mar- garet Hamburg, MD, former assistant secretary for planning and evaluation, Department of Health and Human Services (DHHS); Robert Knouss, MD, Office of Emergency Preparedness, DHHS; Brian Malkin, Esq, formerly with the FDA; and Stuart Nightingale, MD, Office of the Assistant Secretary for Planning and Evalu- ation, DHHS.
Funding/Support: Funding for this study primarily was
provided by each participant’s institution or agency. The Johns Hopkins Center for Civilian Biodefense Stud- ies provided travel funds for 5 of the group.
Disclaimers: In some instances, the indications, dos-
ages, and other information in this article are not con- sistent with current approved labeling by the US Food and Drug Administration (FDA). The recommenda- tions on use of drugs and vaccine for uses not ap- proved by the FDA do not represent the official views of the FDA nor of any of the federal agencies whose scientists participated in these discussions. Unlabeled uses of the products recommended are noted in the sections of this article in which these products are dis- cussed. Where unlabeled uses are indicated, informa- tion used as the basis for the recommendation is discussed.
The views, opinions, assertions, and findings con- tained herein are those of the authors and should not be construed as official US Department of Defense or US Department of Army positions, policies, or deci- sions unless so designated by other documentation. Additional Articles: This article is the fifth in a series entitled Medical and Public Health Management Fol- lowing the Use of a Biological Weapon: Consensus Statements of the Working Group on Civilian Biode- fense. See references 2 through 5.
Dostları ilə paylaş: |
